Defence Therapeutics Unveils New Securities for Debenture Financing: A Strategic Move for Future Growth
Defence Therapeutics Inc. Announces New Unsecured Convertible Debentures Offering Overview Vancouver, British Columbia–(Newsfile Corp. – November 14, 2024) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines,…